ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 934-940

  Mi, Y ^a   Lou, L ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Multidrug resistance; P glycoprotein; ZD6474

Indexed keywords

DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; NAVELBINE; RHODAMINE 123; VANDETANIB; VERAPAMIL;

ARTICLE; BREAST CANCER; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA;

ADENOSINE TRIPHOSPHATASES; ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; P-GLYCOPROTEIN; PIPERIDINES; QUINAZOLINES; RHODAMINE 123; TUMOR CELLS, CULTURED;

EID: 34948887693     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603985     Document Type: Article

References (22)

1. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, Perez-Victoria JM (2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65: 4852-4860
2. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33: 503-511
3. Borst P, Elferink RO (2002) Mammalian ABC transporter in health and disease. Annu Rev Biochem 71: 537-592
4. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556
5. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358
6. Garrigues A, Nugier J, Orlowski S, Ezan E (2002) A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 305: 106-114
7. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587: 318-325
8. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16: 1391-1397
9. Kerr KM, Sauna ZE, Ambudkar SV (2001) Correlation between steady-state ATP hydrolysis and vanadate induced ADP trapping in human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 276: 8657-8664
10. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343
11. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959
12. Ludescher C, Gattringer C, Drach J, Hofmann J, Grunicke H (1991) Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye Rhodamine 123. Blood 78: 1385-1387
13. Massarelli E, Herbst RS (2006) Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 33: 9-16
14. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16: 61-68
15. Orlowski S, Mir LM, Belehradek Jr J, Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317: 515-522
16. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65: 1485-1495
17. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20: 5615-5625
18. Ryan AJ, Wedge SR (2005) ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92: 6-13
19. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etoposide resistance. Cancer Res 54: 152-158
20. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5: 1883-1894
21. Wang C, Zhang JX, Shen XL, Wan CK, Tse AK, Fong WF (2004) Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem Pharmacol 68: 843-855
22. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949